INTRODUCTION
============

Nonalcolic fatty liver disease (NAFLD) is a disorder of a wide spectrum of symptoms including those of simple steatosis without any inflammation or fibrosis, steatosis with nonspecific inflammation, and steatosis accompanied by inflammation and fibrosis, namely nonalcoholic steatohepatitis (NASH)^[@b1-kjim-19-1-19-4]--[@b3-kjim-19-1-19-4])^. NASH is a kind of hepatitis with pathologic findings similar to those of alcoholic hepatitis in nonalcoholics^[@b1-kjim-19-1-19-4],\ [@b2-kjim-19-1-19-4])^. Since Ludwig and colleagues for the first time described this disease in 1980^[@b4-kjim-19-1-19-4])^, the seriousness of this disorder has been being increasingly recognized, because it may progress to cirrhosis, hepatic failure, and even hepatocellular carcinoma^[@b5-kjim-19-1-19-4]--[@b8-kjim-19-1-19-4])^. Several conditions such as an advanced age, obesity, DM or insulin resistance, hyperlipidemia, and female gender have been reported as predisposing factors in this disorder^[@b1-kjim-19-1-19-4],[@b4-kjim-19-1-19-4],[@b9-kjim-19-1-19-4]--[@b12-kjim-19-1-19-4])^. And in several articles^[@b3-kjim-19-1-19-4],\ [@b6-kjim-19-1-19-4],\ [@b13-kjim-19-1-19-4]--[@b15-kjim-19-1-19-4])^, a few conditions, such as an advanced age, type II DM, obesity, and increased AST/ALT ratio have been reported to be the conditions that can lead to the development of severe fibrosis. There have been only few Korean reports^[@b16-kjim-19-1-19-4],\ [@b17-kjim-19-1-19-4])^ on this subject, and the results are not fully consistent with those of other reports. The aim of this study was to identify possible factors that may influence the pathological severity, such as steatosis, inflammation, and fibrosis in Korean NAFLD patients.

MATERIALS AND METHODS
=====================

1.. Patient Population
----------------------

Reports of 933 liver biopsies which were done between year 1998 and 2002 were analysed retrospectively. Different degrees of steatosis were found in 60 patients at microscopic examination, and, finally, 43 patients with NAFLD were reviewed after clinical exclusion of liver diseases, such as alcoholic liver disease, viral hepatitis, autoimmune hepatitis, drug-induced hepatitis, primary biliary cirrhosis, Wilson's disease, hemochromatosis, biliary obstruction, secondary nonalcoholic steatohepatitis, etc. The alcohol intake below 40 g/week was applied as a criterion for exclusion of alcoholic liver disease. Patients who had experienced gastrointestinal surgery or taken drugs^[@b1-kjim-19-1-19-4],\ [@b3-kjim-19-1-19-4])^ which may induce hepatic steatosis, such as corticosteroids, estrogens, methotrexate, tetracycline, calcium channel blockers, or amiodarone were excluded.

2.. Methods
-----------

Liver biopsy was done with employment of ultrasonography in all patients, stained with hematoxylin-eosin and Masson's trichrome. All biopsy specimens were reviewed again by one pathologist. The grading and staging system proposed by Brunt and et al.^[@b18-kjim-19-1-19-4])^ was used to classify the severity of the disease; i.e., the degree of steatosis was graded as 1 (mild), 2 (moderate), and 3 (severe), based on the percent of hepatocytes in the given biopsy specimen. The necroinflammatory activity was also graded as 1 (mild), 2 (moderate), and 3 (severe). Because there was only one patient whose necroinflammatory activity was graded 3 in this study, the comparison was done between two groups, "grade 1" and "grade 2 or more," for the purpose of the statistical processing. Fibrosis was classified into stages 0 (none), 1 (pericellular or perisinusoidal), 2 (periportal), 3 (bridging), and 4 (cirrhosis). The disease entity "NASH" was considered only when, at least, minimal fibrosis was present, and other cases were considered as "simple steatosis" regardless of the necroinflammatory activity. Presence of Mallory's hyaline was reported in all specimen. Age, gender, body mass index (BMI), presence of DM or hypertension, serum or blood tests, such as the white blood cell count (WBC), hemoglobin (Hb), platelets, total protein, albumin, total and direct bilirubin, alkaline phosphatase (ALP), aspartate transaminase (AST), alanine transaminase (ALT), AST/ALT ratio, triglyceride (TG), cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), prothrombin time (PT) prolongation, partial thromboplastin time (PTT), type IV collagen, and hyaluronic acid level were reviewed. The patient was considered obese when BMI exceeded 25 and DM case, if there was a documented administration of oral hypoglycemic agents or insulin, with the fasting glucose level exceeding 125 mg/dL on 2 occasions, or random glucose level exceeding 200 mg/dL. Hypertension was considered when the patient had been taking antihypertensive medicine or when diastolic blood pressure exceeding 90 mmHg or systolic blood pressure exceeding 140 mmHg was noted more than on 2 separate days.

3.. Statistical analysis
------------------------

The SPSS statistical package 11.0 (SPSS Inc., Chicago, IL., U.S.A.) was used for the statistical analysis. All the data were summarized by mean±SD (standard deviation) for continuous variables and by frequency or percentage for categorical variables. The values of the variables were compared among each grades of steatosis and the necroinflammatory activity. The comparison was also done in respect of each stage of fibrosis and between the groups of simple steatosis and NASH. The univariate analysis was performed using Mann-Whitney test for comparison of two groups and Kruscal-Wallis test for more than two groups. Chi-square test was used for comparison of the frequency data. Values of *p* less than 0.05 were considered as "significant" and values of *p* between 0.05 to 0.1 were considered as "tending to significant" statistically. The multiple regression analysis was used to identify the independent effects of significant variables on steatosis, the necroinflammatory activity, and fibrosis.

RESULTS
=======

1.. Patients' demographic and basic laboratory data
---------------------------------------------------

The main clinical and laboratory data of the patients of the study are summarized in [Table 1](#t1-kjim-19-1-19-4){ref-type="table"}. Thirty four (79.1%) patients were male. The mean age was 32.9 years. Mean BMI was 26.8, and the obese patients, whose BMI exceed 25.0, were thirty (69.8%). Three (7.0%) patients had DM and six (14.0%) patients had hypertension. Only three (7.0%) patients had AST/ALT ratio above 1.

2.. Histologic findings
-----------------------

The biopsy findings are summarized in [Table 2](#t2-kjim-19-1-19-4){ref-type="table"}. The grades of steatosis were 1 in 9 (20.9%), 2 in 10 (23.3%), and 3 in 24 (55.8%) patients, respectively. The grades of the necroinflammatory activity were 1, 2, and 3 in 33 (76.8%), 9 (20.9%), and 1 (2.3%) patients, respectively. There were 9 (20.9%) simple steatosis and 34 (79.1%) NASH patients. The ostages of fibrosis were 0 in 9 (20.9%), 1 in 11 (25.6%), 2 in 16 (37.2%), and 3 in 7 (16.3%) patients, respectively. There were no patients with fibrosis stage 4. Mallory bodies were found in 7 (16.3%) patients.

3.. Factors associated with the degree of steatosis, necroinflammatory activity, and fibrosis
---------------------------------------------------------------------------------------------

In the univariate analysis ([Table 3](#t3-kjim-19-1-19-4){ref-type="table"}), there was a significant difference in the direct bilirubin concentration among the 3 grades groups of steatosis (*p*=0.025), but the mean levels were within the normal range. The degree of steatosis by DM (*p*=0.076), total bilirubin concentration (*p*=0.055), AST (*p*=0.057), and serum cholesterol level (*p*=0.064). None of these variables were significant independently in the multivariate analysis.

Though the patients of the advanced age (*p*=0.082) and low hemoglobin concentration (*p*=0.056) showed a tendency to have a more severe activity, there were no independent factors which could be regarded as directly associated with the degree of the necroinflammatory activity ([Table 4](#t4-kjim-19-1-19-4){ref-type="table"}).

Age (*p*=0.034), BMI (*p*\<0.001), obesity (*p*=0.011), and the platelet count (p=0.001) showed a significant correlation with the stage of fibrosis in the univariate analysis ([Table 5](#t5-kjim-19-1-19-4){ref-type="table"}). Of them, age (*p*=0.032), BMI (*p*\<0.001), and the platelet count (*p*=0.009) also showed a significant correlation with the stage of fibrosis in the multivariate analysis ([Table 6](#t6-kjim-19-1-19-4){ref-type="table"}). The significant difference results from the different values of the stage 3 group by the different values of the stage 3 group ([Figure 1](#f1-kjim-19-1-19-4){ref-type="fig"}).

4.. Factors associated with NASH
--------------------------------

When compared by the presence of NASH, BMI (*p*=0.002) and obesity (*p*=0.001) were related to the presence of it in the univariate analysis ([Table 7](#t7-kjim-19-1-19-4){ref-type="table"}). With the cut-055 BMI value of 26.0 in diagnosing NASH, the sensitivity and specificity was 76% and 89%, respectively ([Figure 2](#f2-kjim-19-1-19-4){ref-type="fig"}).

DISCUSSION
==========

The pathologic findings of NASH are similar to those in alcoholic hepatitis^[@b1-kjim-19-1-19-4])^, but there are some inconsistencies in the diagnosis of this disease due to different diagnostic criteria applied in the studies, on which the reports have been published. Although some studies used expanded criteria, which require only nonspecific inflammation combined with steatosis, to diagnose NASH^[@b3-kjim-19-1-19-4],[@b5-kjim-19-1-19-4],\ [@b11-kjim-19-1-19-4],[@b19-kjim-19-1-19-4],[@b20-kjim-19-1-19-4])^, other studies used criteria which impose strictly specific conditions, such as hepatocyte ballooning degeneration, fibrosis, and neutrophilic infiltration with or without Mallory hyaline^[@b2-kjim-19-1-19-4],\ [@b4-kjim-19-1-19-4],\ [@b6-kjim-19-1-19-4],\ [@b9-kjim-19-1-19-4],\ [@b10-kjim-19-1-19-4])^. In previously published two Korean studies^[@b16-kjim-19-1-19-4],[@b17-kjim-19-1-19-4])^, the expanded criteria were used to diagnose NASH. In this study, we used only strictly specific criteria to diagnose NASH, because recent studies report that the prognosis of NAFLD patients differs considerably in respect to the presence of fibrosis^[@b1-kjim-19-1-19-4]--[@b3-kjim-19-1-19-4])^. We considered three factors proposed by the Brunt et al.^[@b18-kjim-19-1-19-4])^ to describe the histology of NAFLD as variables representing the severity of this disease. They are the grades of steatosis, the grades of the necroinflammatory activity, and the stage of fibrosis. Then several clinical and laboratory factors which effect the degree of each variable were analyzed.

In general, several conditions, such as obesity, DM or insulin resistance, hyperlipidemia, hypertension, and other metabolic disorders have been known as causes of steatosis^[@b1-kjim-19-1-19-4],\ [@b4-kjim-19-1-19-4],\ [@b9-kjim-19-1-19-4]--[@b12-kjim-19-1-19-4],\ [@b22-kjim-19-1-19-4],\ [@b23-kjim-19-1-19-4])^. But in this retrospective study, the influence of the above factors on the development of steatosis couldn't be analyzed, because there was no control group.

Although in many published articles^[@b23-kjim-19-1-19-4]--[@b25-kjim-19-1-19-4])^, the serum transaminase level, such as AST or ALT, has been reported to strongly correlate with the degree of the necroinflammatory activity in liver diseases, but report with different also exist^[@b26-kjim-19-1-19-4])^. In several reports, the correlation between the serum transaminase level and the necroinflammatory activity was poor or absent^[@b18-kjim-19-1-19-4],\ [@b27-kjim-19-1-19-4])^. Our study also shows no statistically significant factors, which effect the degree of the necroinflammatory activity.

Several conditions, such as obesity, type 2 DM or insulin resistance, an advanced age, and an increased AST/ALT ratio have been identified as risk factors of the development and progression of fibrosis in a number of previous reports^[@b3-kjim-19-1-19-4],\ [@b6-kjim-19-1-19-4],\ [@b13-kjim-19-1-19-4]--[@b15-kjim-19-1-19-4],\ [@b28-kjim-19-1-19-4],\ [@b29-kjim-19-1-19-4])^. In Korea, BMI was reported as a unique factor, which was associated with the development of fibrosis in both two previous reports,^[@b16-kjim-19-1-19-4],\ [@b17-kjim-19-1-19-4])^ and a low ALT level, besides BMI, was reported to add up to the severity of fibrosis in one report^[@b16-kjim-19-1-19-4])^. Our results are consistent with those of previous Korean reports in the stipulation that BMI is a unique factor, which influences the development of fibrosis. The cut-off BMI value of 26.0 was relevant for the diagnosis of NASH with the sensitivity and specificity of 76% and 89%, respectively. In terms of the severity of fibrosis, our results are not consistent with previous Korean reports in respect of age, platelet count, and ALT level. Though a low platelet count appeared to be related to the seventy of fibrosis, only one patient with severe fibrosis showed thrombocytopenia in our study. As the disease progresses from mild fibrosis to cirrhosis, the platelet count is known to decrease due to the disturbed thrombopoietin synthesis in viral hepatitis^[@b30-kjim-19-1-19-4])^. Further studies seems to be needed to assess the application of this phenomenon in NAFLD or NASH. The two laboratory variables, which are known to strongly correlate with the degree of fibrosis, type IV collagen and hyaluronic acid, were examined only in 18 patients. Being not statistically significant as they are, the values of these variables tend to be high in the fibrosis stage 3 group.

CONCLUSION
==========

No significant factors related to the severity of steatosis and the necroinflammatory activity seem to have been found, but BMI, age, and platelet count may have a certain value for the prognosis of the development and progress of fibrosis.

![The distribution of age (A), BMI (B), and platelet count (C) according to the stage of fibrosis. In all three above variables, the statistically significant differences were taken from radically different values of the stage 3 group.](kjim-19-1-19-4f1){#f1-kjim-19-1-19-4}

![ROC curve for diagnosis of NASH with BMI. Cut-off BMI value of 26.0 was relevant for theto diagnosis of NASH, with sensitivity and specificity of 76% and 89%, respectively (BMI : body mass index).](kjim-19-1-19-4f2){#f2-kjim-19-1-19-4}

###### 

Patient demographics and basic laboratory data (n=43)

  Variables                                                                 Value/Number
  ------------------------------------------------------------------------- --------------
  Age (years)                                                               32.9 ±15.8
  Gender (Male)                                                             34 (79.1%)
  BMI                                                                       26.8±3.5
  Obesity (BMI\>25)                                                         30 (69.8%)
  Diabetes mellitus (+)                                                     3 (7.0%)
  Hypertension (+)                                                          6 (14.0%)
  WBC (/mm3)                                                                7206± 1437
  Hb (g/dL)                                                                 14.7± 1.4
  Platelet (×1000/mm^3^)                                                    255± 63
  Protein (g/dL)                                                            7.5± 0.6
  Albumin (g/dL)                                                            4.7± 0.4
  T-Bilirubin (mg/dL)                                                       0.9± 0.4
  D-Bilirubin (mg/dL)                                                       0.3± 0.2
  ALP (IU/L)                                                                93.8± 51.8
  AST (IU/L)                                                                72.6± 39.4
  ALT (IU/L)                                                                133.8± 71.4
  AST/ALT ratio (\>1)                                                       3 (7.0%)
  TG (mg/dL)                                                                190.8± 93.7
  Chol (mg/dL)                                                              189.3± 31.6
  HDL (mg/dL)                                                               41.4± 8.1
  LDL (mg/dL)                                                               134.6± 34.7
  Type IV collagen (ng/mL)[\*](#tfn2-kjim-19-1-19-4){ref-type="table-fn"}   4.3± 1.6
  Hyaluronic acid (ng/mL)[\*](#tfn2-kjim-19-1-19-4){ref-type="table-fn"}    25.6± 5.2

All values are described as mean±SD. BMI, body mass index; WBC, white blood cell; Hb, hemoglobin; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TG, triglyceride; Chol, cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein

Total number of subject is 18.

###### 

Histologic data of the study group (n=43)

                                        Number of Patients
  ------------------------------------- --------------------
  Grade of steatosis                    
    1                                   9 (20.9%)
    2                                   10 (23.3%)
    3                                   24 (55.8%)
  Grade of necroinflammatory activity   
    1                                   33 (76.8%)
    2                                   9 (20.9%)
    3                                   1 (2.3%)
  Stage of fibrosis                     
    0                                   9 (20.9%)
    1                                   16 (37.2%)
    2                                   11 (25.6%)
    3                                   7 (16.3%)
    4                                   0 (0.0%)
  Mallory bodies                        7 (16.3%)

###### 

Univariate comparison among groups according to the degree of steatosis

                                                                            Grade of steatosis                                
  ------------------------------------------------------------------------- -------------------- -------------- ------------- -------
  N                                                                         9                    10             24            
  Age (years)                                                               42.7 ±18.7           31.7±16.8      29.7 ±13.2    0.176
  Gender (Male)                                                             7 (77.8%)            8 (80.0%)      19 (79.2%)    0.993
  BMI                                                                       25.7 ±2.7            27.1 ±5.2      27.1 ±2.9     0.668
  Obesity (BMI\>25)                                                         5 (55.6%)            6 (60.0%)      19 (79.2%)    0.314
  Diabetes mellitus (+)                                                     2 (22.2%)            1 (10.0%)      0 (14.3%)     0.076
  Hypertension (+)                                                          1 (11.1%)            0 (0%)         5 (20.8%)     0.269
  WBC (/mm3)                                                                7054± 1799           7397± 1345     7184± 1382    0.838
  Hb (g/dL)                                                                 14.1 ±1.2            14.8±1.5       14.9±1.4      0.317
  Platelet (×1000/mm3)                                                      243 ±77.4            244 ±68.1      264 ±55.3     0.822
  Protein (g/dL)                                                            7.8 ±0.8             7.5±0.7        7.5 ±0.5      0.555
  Albumin (g/dL)                                                            4.5 ±0.4             4.6±0.4        4.7 ±0.4      0.145
  T-Bilirubin (mg/dL)                                                       0.9 ±0.4             1.1 ±0.5       0.8 ±0.2      0.056
  D-Bilirubin (mg/dL)                                                       0.3 ±0.2             0.4 ±0.2       0.3 ±0.1      0.025
  ALP (IU/L)                                                                86.8 ±30.6           107.6±90.9     90.6 ±35.0    0.555
  AST (IU/L)                                                                72.6 ±49.0           57.0±37.7      92.1 ±51.3    0.057
  ALT (IU/L)                                                                126.2±71.1           125.1 ±85.3    140.3 ±67.8   0.760
  AST/ALT ratio (\>1)                                                       0 (0%)               0 (0%)         3 (12.5%)     0.279
  TG (mg/dL)                                                                169.2 ±73.8          168.2 ±100.9   205.6 ±97.0   0.460
  Chol (mg/dL)                                                              192.2 ±38.5          169.6±28.5     196.5 ±27.6   0.064
  HDL (mg/dL)                                                               42.2 ±2.9            40.1 ±7.4      41.8 ±9.5     0.901
  LDL (mg/dL)                                                               135.9 ±44.3          117.2±34.2     141.2 ±31.2   0.361
  Type IV collagen (ng/mL)[\*](#tfn4-kjim-19-1-19-4){ref-type="table-fn"}   3.4 ±0.8             4.4±1.1        4.6 ±2.1      0.262
  Hyaluronic acid (ng/mL)[\*](#tfn4-kjim-19-1-19-4){ref-type="table-fn"}    28.3 ±5.7            26.8 ±1.8      24.0 ±6.4     0.588
  Necroinflammatory grade                                                   1.33 ±0.71           1.20 ±0.42     1.25 ±0.44    0.952
  Fibrosis stage                                                            1.44 ± 1.13          1.40 ±1.08     1.33 ±0.96    0.972
  Mallory body (+)                                                          4 (25%)              1 (9.1%)       2 (28.6%)     0.769

All values are described as mean±SD. BMI, body mass index; WBC, white blood cell; Hb, hemoglobin; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TG, triglyceride; Chol, cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein

Total number of subject is 18.

###### 

Univariate comparison among groups according to the degree of necroinflammatory activity

                                                                            Grade of necroinflammatory activity                 
  ------------------------------------------------------------------------- ------------------------------------- ------------- -------
  N                                                                         33                                    10            
  Age (years)                                                               30.1 ±13.8                            42.0 ±19.0    0.082
  Gender (Male)                                                             28 (84.8%)                            5 (15.2%)     0.177
  BMI                                                                       26.6 ±3.6                             27.7 ±3.0     0.249
  Obesity (BMI\>25)                                                         22 (66.7%)                            8 (80.0%)     0.696
  Diabetes mellitus (+)                                                     1 (3.0%)                              2 (20.0%)     0.130
  Hypertension (+)                                                          4 (12.1%)                             2 (20.0%)     0.611
  WBC (/mm^3^)                                                              7110± 1309                            7523± 1842    0.561
  Hb (g/dL)                                                                 14.9±1.4                              14.0±1.4      0.056
  Platelet (X1000/mm^3^)                                                    257 ±57.6                             247 ±80.0     0.561
  Protein (g/dL)                                                            7.6 ±0.6                              7.3 ±0.5      0.286
  Albumin (g/dL)                                                            4.7 ±0.4                              4.6 ±0.3      0.944
  T-Bilirubin (mg/dL)                                                       0.9 ±0.4                              0.8 ±0.2      0.452
  ALP (IU/L)                                                                87.6 ±37.6                            114.2 ±82.9   0.341
  AST (IU/L)                                                                69.3 ±38.2                            83.3 ±43.5    0.273
  ALT (IU/L)                                                                137.5 ±75.6                           121.6 ±56.9   0.640
  AST/ALT ratio (\>1)                                                       2 (6.1%)                              1 (10.0%)     0.558
  TG (mg/dL)                                                                194.8 ±98.1                           177.3 ±81.0   0.862
  Chol (mg/dL)                                                              189.5 ±30.4                           188.6 ±36.9   0.854
  HDL (mg/dL)                                                               40.1 ±7.2                             45.9 ±9.5     0.120
  LDL (mg/dL)                                                               137.0 ±32.7                           126.8 ±42.2   0.307
  Type IV collagen (ng/mL)[\*](#tfn6-kjim-19-1-19-4){ref-type="table-fn"}   4.6 ±1.4                              3.4 ±2.4      0.382
  Hyaluronic acid (ng/mL)[\*](#tfn6-kjim-19-1-19-4){ref-type="table-fn"}    26.5 ±2.6                             22.6 ±10.4    0.645
  Steatosis grade                                                           2.33 ±0.82                            2.40 ±0.84    0.832
  Fibrosis stage                                                            1.21 ±0.99                            1.90 ±0.88    0.072
  Mallory body (+)                                                          4 (12.1%)                             3 (30.0%)     0.325

All values are described as mean±SD. BMI, body mass index; WBC, white blood cell; Hb, hemoglobin; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TG, triglyceride; Chol, cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein

Total number of subject is 18.

###### 

Univariate comparison among groups according to the degree of fibrosis

                                                                            Stage of Fibrosis                                          
  ------------------------------------------------------------------------- ------------------- ------------ ------------ ------------ -------
  N                                                                         9                   16           11           7            
  Age (years)                                                               27.1 ±12.6          27.5 ±9.9    34.2 ±16.0   50.4 ±19.2   0.034
  Gender (Male)                                                             8 (88.9%)           14 (87.5%)   8 (72.7%)    4 (57.1%)    0.087
  BMI                                                                       23.5±3.3            26.6 ±1.6    26.9 ±3.0    31.4±2.7     0.000
  Obesity (BMI\>25)                                                         2 (22.2%)           14 (87.5%)   7 (63.6%)    7 (100%)     0.011
  DM (+)                                                                    0 (0%)              1 (6.3%)     1 (9.1%)     1 (14.3%)    0.263
  Hypertension (+)                                                          1 (11.1%)           2 (12.5%)    0 (0%)       3 (42.9%)    0.306
  WBC (/mm3)                                                                7775± 876           6966± 1164   7719± 1586   6219± 1892   0.102
  Hb (g/dL)                                                                 15.3±1.0            14.9±1.5     14.3±1.4     14.2±1.7     0.170
  Platelet (×1000/mm^3^)                                                    263± 55.7           290± 46.5    252± 37.5    168± 57.3    0.001
  Protein (g/dL)                                                            7.6±0.6             7.5 ±0.7     7.4±0.7      7.5±0.6      0.901
  Albumin (g/dL)                                                            4.7±0.3             4.6 ±0.4     4.7±0.4      4.6±0.4      0.603
  T-Bilirubin (mg/dL)                                                       0.9±0.5             1.0 ±0.4     0.8±0.1      0.9±0.3      0.787
  ALP (IU/L)                                                                99.0±41.1           91.2 ±67.1   95.5 ±51.1   90.3±28.3    0.526
  AST (IU/L)                                                                54.8 ±14.4          72.5 ±44.0   74.8±36.3    92.1 ±51.3   0.559
  ALT (IU/L)                                                                136± 73             125± 67      142± 65      137± 101     0.867
  AST/ALT ratio (\>1)                                                       1 (11.1%)           2 (12.5%)    0 (0%)       0 (0%)       0.196
  TG (mg/dL)                                                                218± 116            158± 80      210± 96      192± 93      0.485
  Chol (mg/dL)                                                              193± 36             180± 30      207± 28      179± 29      0.122
  HDL (mg/dL)                                                               41.0±6.4            39.1 ±7.7    45.6±9.8     40.4±7.1     0.385
  LDL (mg/dL)                                                               142± 42             132± 36      146± 27      113 ±30      0.178
  Type IV collagen (ng/mL)[\*](#tfn8-kjim-19-1-19-4){ref-type="table-fn"}   3.9±1.8             3.9 ±2.0     5.0±0.5      5.2          0.566
  Hyaluronic acid (ng/mL)[\*](#tfn8-kjim-19-1-19-4){ref-type="table-fn"}    26.6±2.1            25.0 ±6.9    25.6±1.1     30.1         0.420
  Steatosis grade                                                           2.33± 0.87          2.37 ±0.81   2.45±0.82    2.14± 0.90   0.872
  Necroinflammatory grade                                                   1.00± 0.00          1.25± 0.45   1.27± 0.47   1.57± 0.79   0.207
  Mallory body (+)                                                          0 (0%)              4 (25%)      1 (9.1%)     2 (28.6%)    0.354

All values are described as mean±SD. BMI, body mass index; WBC, white blood cell; Hb, hemoglobin; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TG, triglyceride; Chol, cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein

Total number of subject is 18.

###### 

Multiple regression analysis about the association between the degree of fibrosis and related variables

  value     Regression Coefficient   SE of Regression Coefficient   F value   Significance
  --------- ------------------------ ------------------------------ --------- --------------
  BMI       0.536                    0.030                          26.978    0.000
  Age       0.241                    0.007                          4.920     0.032
  Platlet   −0.300                   0.000                          7.640     0.009
  R^2^      0.583                                                             

###### 

Univariate comparison between groups according to the presence of fibrosis

                                                                             Presence of fibrosis                 
  -------------------------------------------------------------------------- ---------------------- ------------- -------
  N                                                                          9                      34            
  Age (years)                                                                27.1 ±12.6             34.4 ±16.3    0.164
  Gender (Male)                                                              8 (88.9%)              26 (76.5%)    0.657
  BMI                                                                        23.5 ±3.3              27.7±3.0      0.001
  Obesity (BMI\>25)                                                          2 (22.2%)              28 (82.4%)    0.001
  Diabetes mellitus (+)                                                      0 (0.0%)               3 (8.8%)      1.000
  Hypertension (+)                                                           1 (11.1%)              5 (14.7%)     1.000
  WBC (/mm3)                                                                 7775± 876              7056± 1526    0.114
  Hb (g/dL)                                                                  15.3±1.0               14.6±1.5      0.066
  Platelet (×1000/mm^3^)                                                     263 ±55.7              253 ±64.9     0.687
  Protein (g/dL)                                                             7.6 ±0.6               7.5 ±0.6      0.491
  Albumin (g/dL)                                                             4.7 ±0.3               4.6 ±0.4      0.641
  T-Bilirubin (mg/dL)                                                        0.9 ±0.5               0.9 ±0.3      0.751
  ALP (IU/L)                                                                 99.0 ±41.1             92.4 ±54.7    0.269
  AST (IU/L)                                                                 54.8 ±14.4             77.3 ±42.6    0.256
  ALT (IU/L)                                                                 135.8 ±72.8            133.3 ±72.1   0.731
  AST/ALT ratio (\>1)                                                        1 (11.1%)              2 (5.9%)      0.515
  TG (mg/dL)                                                                 217.7±116.5            184.1 ±88.3   0.509
  Chol (mg/dL)                                                               192.9 ±35.6            188.4 ±31.0   0.698
  HDL (mg/dL)                                                                41.0 ±6.4              41.5 ±8.6     0.983
  LDL (mg/dL)                                                                142.7 ±42.2            132.5 ±33.2   0.537
  Type IV collagen (ng/mL)[\*](#tfn10-kjim-19-1-19-4){ref-type="table-fn"}   3.9 ±1.8               4.4 ±1.7      0.778
  Hyaluronic acid (ng/mL)[\*](#tfn10-kjim-19-1-19-4){ref-type="table-fn"}    26.6 ±2.1              25.5 ±5.5     0.779
  Steatosis grade                                                            2.33 ±0.87             2.35 ±0.81    0.960
  Necroinflammatory activity                                                 1.00 ±0.00             1.32 ±0.54    0.067
  Mallory body (+)                                                           0 (0.0%)               7 (16.3%)     0.314

All values are described as mean±SD. BMI, body mass index; WBC, white blood cell; Hb, hemoglobin; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TG, triglyceride; Chol, cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein

Total number of subject is 18.
